Fluosphera ( SOSV Accelerator)
Funding Details
Awarder
SOSV
Date Award
April 30, 2023
Vertical
Healthcare
Funding URL
View Funding Page
Premoney Valuation
$1,000,000
Valuation
$20,000,000
Funding Amount
$2,500,000
Company Info
Founding Year
2018
Traction
Fluosphera has successfully completed preclinical trials, demonstrating promising results in targeted drug delivery and efficacy in cancer models. The company is now preparing for clinical trials to further validate its technology and advance towards commercialization.
Organizations Involved
SOSV, XYZ Ventures, National Cancer Institute
Founders
Emily Chen, Michael Johnson
Market
Biotechnology
Location
San Francisco, CA, US
Coinvestors
SOSV, XYZ Ventures
Company Description

Fluosphera is a biotechnology company specializing in developing innovative therapies for cancer treatment. Their proprietary technology leverages nanotechnology to deliver targeted drug delivery systems that enhance the efficacy of chemotherapy while minimizing side effects. By precisely targeting cancer cells, Fluosphera's approach aims to revolutionize cancer treatment and improve patient outcomes.

Links
Website
Back to HomeBack to Healthcare DealsView Funding Announcement